Opportunity Title: FDA Evaluation of Quality of Multi-Component OTC Drug Products
Opportunity Reference Code: FDA-CDER-2025-1476

Organization U.S. Food and Drug Administration (FDA)

Reference Code FDA-CDER-2025-1476

How to Apply ***To submit your application, scroll to the bottom of this opportunity and click APPLY.***

A complete application consists of:

- An application
- Transcripts – Click here for detailed information about acceptable transcripts
- A current resume/CV, including academic history, employment history, relevant experiences, and publication list
- One educational or professional recommendation

All documents must be in English or include an official English translation.

If you have questions, send an email to ORISE.FDA.CDER@orau.org. Please include the reference code for this opportunity in your email.

Connect with ORISE...on the GO! Download the new ORISE GO mobile app in the Apple App Store or Google Play Store to help you stay engaged, connected, and informed during your ORISE experience and beyond!

Application Deadline 3/31/2025 3:00:00 PM Eastern Time Zone

Description ***Applications will be reviewed on a rolling-basis.**

FDA Office and Location: A research opportunity is available within the Food and Drug Administration (FDA) in The Center for Drug Evaluation and Research (CDER), Office of Pharmaceutical Quality Research (OPQR), Office of Pharmaceutical Quality (OPQ), located at St. Louis, Missouri.

The Center for Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the U.S. Food and Drug Administration (FDA), CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. This work covers more than just medicines.

Research Project: Some over-the-counter (OTC) drug products contain multiple active pharmaceutical ingredients (API) and require several analytical methods to assess drug product quality. Recalls of multi-component OTC products have occurred due to undeclared levels of APIs, API sub-potency, and presence of impurities. Poor quality OTC products on the market have the potential to cause consumers' harm. To address this quality concern, FDA will conduct research utilizing various analytical techniques to evaluate OTC products and identify opportunities to develop improved methods for their quality evaluation.

Learning Objectives: Under the guidance of the mentor, the participant will gain experience with preparing samples and evaluating the quality of multi-

component OTC products using a variety of analytical techniques, such as high-performance liquid chromatography (HPLC) and dissolution to assess product quality attributes such as potency, impurity, content uniformity, and drug release information. The participant may develop sample preparation procedures using an automatic sample preparation system in conjunction with evaluating opportunities for developing multi-analyte HPLC methods to facilitate product quality evaluations. The participant will learn the skills relevant for the project including laboratory basics for pharmaceutical analysis and scientific software for data analysis. As the project progresses, the participant will gain experience in developing a scientific process, drawing conclusions from their findings, and communicating their results through various channels such as technical reports, meeting presentations, and manuscripts. Overall, the learning objectives aim to equip the participant with skills and knowledge necessary to pursue a career in pharmaceutical research, development, and regulation.

Anticipated Appointment Start Date: 2025. Start date is flexible and will depend on a variety of factors.

Appointment Length: The appointment will initially be for one year, but may be renewed upon recommendation of FDA and is contingent on the availability of funds.

Level of Participation: The appointment is full time.

Citizenship Requirements: This opportunity is available to U.S. citizens, Lawful Permanent Residents (LPR), and foreign nationals. Non-U.S. citizen applicants should refer to the Guidelines for Non-U.S. Citizens Details page of the program website for information about the valid immigration statuses that are acceptable for program participation.

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.

FDA Ethics Requirements

If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or prohibited investment fund financial interest in any amount, or a

relationship with an SRO, except for spousal employment with an SRO, and the individual will not voluntarily divest the financial interest or terminate the relationship, then the individual is not placed at FDA. For additional requirements, see FDA Ethics for Nonemployee Scientists.

FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:

- Non-employee nature of the ORISE appointment;
- Prohibition on ORISE Fellows performing inherently governmental functions;
- Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
- The fact that research materials and laboratory notebooks are the property of the FDA;
- ORISE fellow's obligation to protect and not to further disclose or use non-public information.

Qualifications

The qualified candidate should be currently pursuing or have received a bachelor's, master's, or doctoral degree in the one of the relevant fields. Degree must have been received within the past five years, or anticipated to be received by 6/30/2025.

Preference is given to highly motivated individuals with a doctoral degree in physical sciences (chemistry, pharmaceutical sciences, or related field), but qualified individuals with a master's and bachelor's in physical sciences may also be considered provided the candidate demonstrates strong analytical experience.

Preferred skills:

- Knowledge of and hands-on experience using HPLC, preferably including method development experience.

Point of Contact

Sara Beth Hensley

Eligibility Requirements

- **Degree:** Bachelor's Degree, Master's Degree, or Doctoral Degree received within the last 60 months or anticipated to be received by 6/30/2025 12:00:00 AM.
- **Discipline(s):**
  - **Chemistry and Materials Sciences** (12 👁)

Affirmation

I am a U.S. citizen, or I have lived in the United States for at least 36 out of the past 60 months. (36 months do not have to be consecutive.)
and

Opportunity Title: FDA Evaluation of Quality of Multi-Component OTC Drug Products
Opportunity Reference Code: FDA-CDER-2025-1476

I have read the FDA Ethics Requirements.